Breathe Well Live Well
|
Cinryze® (C1 esterase inhibitor [human]) Data Presented at 2010 Annual Meeting …
PR Newswire (press release) There can be no assurance that that the data presented during the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) … Cinryze(R) (C1 esterase inhibitor [human]) Data Presented at 2010 Annual … |
View full post on asthma – Google News
|
KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy …
MarketWatch (press release) Ecallantide for Treatment of Acute Attacks of Acquired C1 Esterase Inhibitor Deficiency — Nisha S. Patel, MD, Asthma Allergy & Pulmonary Associates, … KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy … |
View full post on asthma – Google News
|
Airway Heat Treatment Has Lasting Effect on Severe Asthma: Presented at CHEST 2010
DG News VANCOUVER — November 5, 2010 — Bronchial thermoplasty (BT) is safe and effective for up to 2 years in patients with severe asthma, … Bronchial Thermoplasty for Asthma Proving Itself in Long Term Trial |
View full post on asthma – Google News
|
Theravance Announces Data From the RELOVAIR(TM) Program to Be Presented at the …
MarketWatch (press release) A total of 13 preclinical and clinical abstracts for RELOVAIR(TM) and its individual components in COPD and asthma were accepted by ERS for presentation, … |
View full post on asthma – Google News
Pearl Therapeutics’ Bronchodilator Combination Therapeutic For COPD To Be Presented At The American Thoracic Society …
Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, announced four upcoming poster presentations at the Annual Meeting of the American Thoracic Society (ATS) to be held at the Ernest N. Morial Convention Center in New Orleans from May 14-19, 2010. Results from Pearl’s …
Read more on Medical News Today